स्लोवेनिया - स्लोवेनियाई - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

amgen europe b.v. - adalimumab - raztopina za injiciranje - adalimumab 20 mg / 0,4 ml - adalimumab

स्लोवेनिया - स्लोवेनियाई - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

amgen europe b.v. - adalimumab - raztopina za injiciranje - adalimumab 40 mg / 0,8 ml - adalimumab

स्लोवेनिया - स्लोवेनियाई - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

abbvie deutschland gmbh & co. kg - adalimumab - raztopina za injiciranje - adalimumab 20 mg / 1 brizga - adalimumab

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

sanofi winthrop industrie - sarilumab - artritis, revmatoidni - imunosupresivi - kevzara v kombinaciji z metotreksat (mtx) je indicirano za zdravljenje zmerno do hudo aktivnim revmatoidnim artritisom (ra) pri odraslih bolnikih, ki so se odzvali neustrezno ali ki so prenašali na eno ali več bolezni spreminjanje proti revmi drog (imunomodulirajočimi). zdravilo kevzara lahko dobite v obliki monoterapije v primeru nestrpnosti do mtx ali kadar je zdravljenje z mtx neprimerno.

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

janssen-cilag international nv - guselkumab - psoriaza - imunosupresivi - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriaza - imunosupresivi - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - imunosupresivi - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - spesolimab - psoriaza - imunosupresivi - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artritis, revmatoidni - imunosupresivi - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 in 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artritis, revmatoidni - imunosupresivi - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.